Published: 19 August 2017
Author(s): Pedro Iglesias
Issue: August 2017

Cancer immunotherapy has proven to be effective in a wide variety of tumors. The use of immune checkpoint blocking monoclonal antibodies has become a standard treatment regimen in some of them as advanced melanoma. However, given the mechanism of action, its use may be associated with immune-related adverse events that may complicate the clinical course and prognosis of patients. Among these are autoimmune endocrine adverse effects, such as hypophysitis, hypo and hyperthyroidism, and adrenal insufficiency.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.